Live Breaking News & Updates on After String Of Multi Billion Acquisitions

Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion, an increase of 5% year-over-year, or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl, and Opdualag, partially offset by Opdivo and Revlimid. Growth Portfolio worldwide revenues increased to $4.8 billion, up 8% or 11% when adjusted for foreign exchange impacts. This increase was primarily driven by higher demand for Reblozyl, O ....

Bristol Myers Squibb , William Blair , Bristol Myers Squibb Co , Legacy Portfolio , Myers Squibb , Stock Market Game , Benzinga Pro , Day Trial , After String Of Multi Billion Acquisitions , Foreign Exchange , Orldwide Revenues ,